The acquisition of Biotest US, a geographical unit of the German-based Biotech AG, for $286m (€247m) sees Grifols, a company based in Catalonia, Spain, increase its presence in North America.
Grifols Shared Services North America will gain access to: 22 Biotest plasma collection centers, two centers currently under construction, two centers under purchase contract, all corporate offices, and roughly 900 employees, as part of the deal.
Biotest’s CEO, Ileana Carlisle said in a press release, “We are excited to be part of the Grifols prestigious global organization and remain steadfast on our mission to secure a quality supply of the raw materials needed to help the thousands of patients that rely on plasma-based therapies.”
Biotest collects plasma at its centers to manufacture critical care therapies in many therapeutic areas.
It wasn’t long since Biotest announced it was relocating its plasma center in Pembroke Pines, Florida, and was aiming to expand its staff.
However, not long prior this, Biotest sold its Boca Raton, Florida site to ADMA Biologics under the agreement that ADMA will have exclusive rights to Biotest’s plasma-derived therapies. One such asset acquired was Biotest’s former lead candidate, RI-002, after its application for approval to the FDA became mired in manufacturing issues and led to a complete response letter.